Atelerix

United Kingdom
Rackheath, England, United Kingdom, NE1 3BZ

Company profile

Atelerix company profile

Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2006-01-01, Year

Headquarters

Postal code
NE1 3BZ
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
7
Total equity funding
$3M
Last funding
Series Unknown / $933,054 / 2025-01-28
Last equity funding
Series Unknown / $933,054
Investors
8
Lead investors
4
Founders
3
Articles
39

Founders and investors

Founders

Che John ConnonMick McLeanStephen Swioklo

Lead investors

ACF InvestorsInnovate UKO2h VenturesUK Innovation & Science Seed Fund

Investors

ACF InvestorsAngels in MedCityFuture Planet CapitalInnovate UKNewable Private Investing